Innovations for Changing the Face of Women’s Reproductive Health Therapeutics

At ObsEva, our passion and expertise in reproductive health and pregnancy therapeutics is helping millions of women worldwide lead healthier and more fulfilling lives.

Nolasiban set to revolutionise fertility

Interview in ‘The Times’ with ObsEva CEO, Ernest Loumaye

Innovation From Conception to Birth and Beyond

ObsEva is advancing a robust pipeline of novel, orally-administered, clinical-stage compounds in the areas of uterine fibroids, endometriosis, assisted reproductive technology, and preterm labor.

Recent Updates

01 Apr 2019

ObsEva SA to Participate in Upcoming Investor Conferences

Read more
29 Mar 2019

Publication of ObsEva SA Invitation to 2019 Annual General Meeting of Shareholders

Read more
27 Mar 2019

Nolasiban Set to Revolutionise Fertility: Interview in 'The Times' with ObsEva CEO, Ernest Loumaye

Read more
13 Mar 2019

ObsEva SA to Present OBE022 Clinical Data for Treatment of Pre-term labor (PTL) at the SRI 66th Annual Scientific Meeting, March 12 -16, 2019

Read more